newsfilter
← Latest News
GlobeNewswire·

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin H1-2024.GLP